Immunomodulators Flashcards
monoclonal antibodies (mAb)
the drug product of a single B cell that is fused/hybridized with a multiple myeloma tumor cell →
you get a hybrid line that is immortal (like its tumor parent) but also make the specific antibody of its B cell parent (monoclonal antibodyproducing cells)! = Hybridoma →
After they make the Ab you want, you take it out of the well, and use it for your purposes→
mAb work by triggering ADCC (more on this in later objective)
5
Examples of monoclonal antibodies as anti-inflammatory agents.
Infliximab - chimeric Ab against TNFα → approved for a lot of inflammatory diseases
Tocilizumab - Anti IL-6 receptor → approved for RA (inflammation)
Murine mAb
- suffix?
[-omab]
The first monoclonals made using B cells directly derived from immunized mice;
Chimeric mAb
[-ximab]
mouse VL and VH domains (V regions)
human C domains
Humanized mAb
[-zumab]
only the CDR’s of the V domains are from the mouse.
Fully human mAb
[-umab]
made entirely of human amino acids
NK (natural killer) cells:
Large granular lymphocytes (LGL) which make up 5-10% of blood lymphocytic cells.
○ NK receptors recognize molecules on the surface of ‘stressed’ or dysregulated cells, such as virally-infected cells or many tumors, which they then kill; therefore, they are part of the innate immune system.
○ They have a second cytotoxic trick available: a special killing mechanism → ADCC
How are NK cells different from CTLs?
○ NK cells are killers with mechanisms VERY similar to those of CTL, but they do not have rearranged V(D)J genes and are not thymic-derived.
Antibody-dependent cell-mediated cytotoxicity (ADCC):
Let’s take cells from a tumor that expresses markers that NK cells recognize via NK receptors → add antibodies (ie: IgG) that can bind to target tumor cells → no effect → add normal blood leukocytes (which include NK cells) → NK cells binds to the Fc end of the antibody → Just like a Killer T cells, NK cells trigger tumor cell death via delivery of lethal signals → induced apoptosis
(If you hadn’t added both antibody and the NK cells, nothing would have happened, so the phenomenon is called ADCC.)
Whats unique about the way that ADCC work?
§ Anyone’s leukocytes can be used; the phenomenon is not MHC-restricted the way CTL-mediated killing is.
§ ADCC works because NK cells also have receptors for the Fc end of IgG (FcγR), and so they have a second, antibody-dependent, way to interact with target cells.
§ We know that many of the new therapeutic monoclonal antibodies (used to modulate the immune response, or treat cancer) work by triggering ADCC.
Describe how a monoclonal antibody against a T cell surface molecule could enhance the activity of a CTL.
Concept was named BiTE for Bispecific T-cell Engager. (Engages CTL)
-Couple together two single-chain engineered antibodies, one against CD19 and one against CD3 →
T cells can bind via their CD3 to CD19+ of B cell lymphoma cells.
This allows a transformed CTL to bind a tumor target with high affinity and chosen specificity, and, like an antibody, no MHC-restriction, and then be triggered via its normal TCR-associated pathway to become a fully-cytotoxic cell.
what type of mAb is it and what does it target?
- Rituximab
- Rituximab: chimeric mAb to CD20 treat NH lymphoma, chronic lymphocytic leukemia RA when anti-TNF therapy fails off lable MS
Use of modified mAbs in tumor diagnosis + treatment
Ibritumomab:
murine mAb against CD20.
It helps chelate Indium and Ytrium and is first FDA approved radioimmunotherapy
mAb images the tumor, Ytrium treats it.